Journal for ImmunoTherapy of Cancer (Nov 2021)
854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models
- Elizabeth Gray,
- Shyra Gardai,
- Kelly Hensley,
- Sean Allred,
- Esther Trueblood,
- John Gosink,
- Katie Snead,
- Michelle Ulrich,
- Alyson Smith,
- Angela Epp,
- Disha Sahetya,
- Julie Hahn,
- Jane Haass,
- Sasha Lucas,
- Rogely Boyce,
- Piper Treuting,
- Chris Frantz,
- Jason Schrum,
- Natalya Nazarenko
Affiliations
- Elizabeth Gray
- 1 Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, UK
- Shyra Gardai
- Seattle Genetics, Inc., Bothell, WA, USA
- Kelly Hensley
- 1Seattle Genetics, Inc., Bothell, USA
- Sean Allred
- 1Seattle Genetics, Inc., Bothell, USA
- Esther Trueblood
- 1Seattle Genetics, Inc., Bothell, USA
- John Gosink
- 1Seattle Genetics, Inc., Bothell, USA
- Katie Snead
- 1Seattle Genetics, Inc., Bothell, WA, USA
- Michelle Ulrich
- Seattle Genetics, Inc., Bothell, WA, USA
- Alyson Smith
- 1Seagen, Inc., Bothell, WA, USA
- Angela Epp
- 1Seagen, Inc., Bothell, WA, USA
- Disha Sahetya
- 1Seagen, Inc., Bothell, WA, USA
- Julie Hahn
- 1Seagen, Inc., Bothell, WA, USA
- Jane Haass
- 1Seagen, Inc., Bothell, WA, USA
- Sasha Lucas
- 1Seagen, Inc., Bothell, WA, USA
- Rogely Boyce
- 2Beechy Ridge ToxPath LLC, Clay, WV, USA
- Piper Treuting
- 1Seagen, Inc., Bothell, WA, USA
- Chris Frantz
- 1Seagen, Inc., Bothell, WA, USA
- Jason Schrum
- 1Seagen, Inc., Bothell, WA, USA
- Natalya Nazarenko
- 1Seagen, Inc., Bothell, WA, USA
- DOI
- https://doi.org/10.1136/jitc-2021-SITC2021.854
- Journal volume & issue
-
Vol. 9,
no. Suppl 2
Abstract
No abstracts available.
